ICUI's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator showed a similar pattern. In 154 of the 204 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 75%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ICUI as a result. In 65 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ICUI just turned positive on November 04, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 35 of 52 cases over the following month. The odds of a continued upward trend are 67%.
ICUI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICUI crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +5.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 189 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The 10-day RSI Indicator for ICUI moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 18 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
ICUI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.964). ICUI has a moderately high P/E Ratio (143.425) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Stochastic Oscillator for NDRA moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 34 similar instances where the indicator exited the overbought zone. In 31 of the 34 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NDRA as a result. In 84 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NDRA turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NDRA moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NDRA crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NDRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NDRA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NDRA's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +3.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NDRA advanced for three days, in 184 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NDRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. NDRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.155) is normal, around the industry mean (67.298). P/E Ratio (-0.773) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NDRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
ICUI | NDRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 99 | |
PRICE GROWTH RATING 1..100 | 40 | 60 | |
P/E GROWTH RATING 1..100 | 97 | 100 | |
SEASONALITY SCORE 1..100 | 36 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ICUI's Valuation (87) in the Medical Specialties industry is in the same range as NDRA (95) in the Biotechnology industry. This means that ICUI’s stock grew similarly to NDRA’s over the last 12 months.
ICUI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that ICUI’s stock grew similarly to NDRA’s over the last 12 months.
ICUI's SMR Rating (89) in the Medical Specialties industry is in the same range as NDRA (99) in the Biotechnology industry. This means that ICUI’s stock grew similarly to NDRA’s over the last 12 months.
ICUI's Price Growth Rating (40) in the Medical Specialties industry is in the same range as NDRA (60) in the Biotechnology industry. This means that ICUI’s stock grew similarly to NDRA’s over the last 12 months.
ICUI's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that ICUI’s stock grew similarly to NDRA’s over the last 12 months.
| ICUI | NDRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| Advances ODDS (%) | 5 days ago 68% | 11 days ago 81% |
| Declines ODDS (%) | 3 days ago 71% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICUI’s FA Score shows that 0 FA rating(s) are green while NDRA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICUI’s TA Score shows that 6 TA indicator(s) are bullish while NDRA’s TA Score has 3 bullish TA indicator(s).
ICUI (@Pharmaceuticals: Other) experienced а +4.16% price change this week, while NDRA (@Medical Specialties) price change was -7.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.79%. For the same industry, the average monthly price growth was +4.31%, and the average quarterly price growth was +18.71%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
ICUI is expected to report earnings on Mar 03, 2027.
NDRA is expected to report earnings on Apr 01, 2027.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, ICUI has been loosely correlated with CLPT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ICUI jumps, then CLPT could also see price increases.
| Ticker / NAME | Correlation To ICUI | 1D Price Change % | ||
|---|---|---|---|---|
| ICUI | 100% | +1.11% | ||
| CLPT - ICUI | 57% Loosely correlated | -0.12% | ||
| ALGN - ICUI | 56% Loosely correlated | +0.81% | ||
| MMSI - ICUI | 53% Loosely correlated | -0.07% | ||
| A - ICUI | 50% Loosely correlated | +0.55% | ||
| COO - ICUI | 49% Loosely correlated | +0.74% | ||
More | ||||
A.I.dvisor tells us that NDRA and GMED have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NDRA and GMED's prices will move in lockstep.
| Ticker / NAME | Correlation To NDRA | 1D Price Change % | ||
|---|---|---|---|---|
| NDRA | 100% | -2.92% | ||
| GMED - NDRA | 29% Poorly correlated | -0.22% | ||
| ICUI - NDRA | 24% Poorly correlated | +1.11% | ||
| CNMD - NDRA | 23% Poorly correlated | +0.22% | ||
| LAB - NDRA | 22% Poorly correlated | +8.60% | ||
| SGHT - NDRA | 21% Poorly correlated | -1.46% | ||
More | ||||